Share on StockTwits

Stock analysts at Jefferies Group decreased their price objective on shares of Sinclair IS Pharma PLC (LON:SPH) from GBX 50 ($0.85) to GBX 45 ($0.76) in a report issued on Tuesday. The firm currently has a “buy” rating on the stock. Jefferies Group’s target price would suggest a potential upside of 48.76% from the stock’s previous close.

Sinclair IS Pharma PLC (LON:SPH) traded down 2.42% on Tuesday, hitting GBX 30.25. The stock had a trading volume of 188,623 shares. Sinclair IS Pharma PLC has a 52 week low of GBX 23.50 and a 52 week high of GBX 34.18. The stock’s 50-day moving average is GBX 31.23 and its 200-day moving average is GBX 30.8.

Other equities research analysts have also recently issued reports about the stock. Analysts at Canaccord Genuity raised their price target on shares of Sinclair IS Pharma PLC from GBX 38 ($0.65) to GBX 44 ($0.75) in a research note on Tuesday, July 15th. They now have a “buy” rating on the stock. Separately, analysts at N+1 Singer reiterated a “buy” rating on shares of Sinclair IS Pharma PLC in a research note on Tuesday, July 15th. They now have a GBX 40 ($0.68) price target on the stock. Finally, analysts at FinnCap reiterated a “buy” rating on shares of Sinclair IS Pharma PLC in a research note on Tuesday, July 15th. They now have a GBX 43 ($0.73) price target on the stock. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Sinclair IS Pharma PLC has a consensus rating of “Buy” and a consensus target price of GBX 36.50 ($0.62).

Sinclair IS Pharma plc is a specialty pharmaceutical company focused on treatments in dermatology, wound care, oncology support and critical care through surface technology and delivery systems.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.